Rahul Singhvi
Known title: DirectorCIK: 0001322731
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Codexis Signs siRNA Manufacturing Deal. Codexis has entered an agreement with an unnamed siRNA drug innovator to use its ECO Synthesis platform for stereo-defined fragment synthesis. This partnership highlights the company's manufacturing capabilities in a growing therapeutic area. The stock is currently trading near its 52-week low, with recent price action showing rejection at support levels.
Transaction History
| KAPA | ▲ Buy | Grant | 19,084 | $0 | 10/8/2025 | View on chart |
| CDXS | ▲ Buy | Grant | 40,983 | $0 | 6/10/2025 | View on chart |
| CDXS | ▲ Buy | Grant | 30,120 | $0 | 6/11/2024 | View on chart |
| CDXS | ▲ Buy | Grant | 34,602 | $0 | 6/13/2023 | View on chart |
| CDXS | ▲ Buy | Grant | 31,347 | $0 | 9/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Kairos Pharma Reports Positive Phase 2 Data for ENV-105
Kairos Pharma announced positive, statistically significant interim efficacy data from a Phase 2 trial of ENV-105 for metastatic prostate cancer. The company noted the drug targets a specific resistance mechanism in the disease. This clinical update is the primary driver behind recent stock movement, occurring while the share price trades well below its 52-week high.
Kairos Pharma Reports Positive Phase 2 Data for ENV-105. Kairos Pharma announced positive, statistically significant interim efficacy data from a Phase 2 trial of ENV-105 for metastatic prostate cancer. The company noted the drug targets a specific resistance mechanism in the disease. This clinical update is the primary driver behind recent stock movement, occurring while the share price trades well below its 52-week high.